Knight Therapeutics Inc.
GUD.TO
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.19% | 13.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.19% | 13.73% | |||
| Cost of Revenue | 2.77% | 5.61% | |||
| Gross Profit | 14.57% | 25.05% | |||
| SG&A Expenses | 12.90% | -1.03% | |||
| Depreciation & Amortization | -11.50% | 44.59% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.69% | 9.39% | |||
| Operating Income | 849.79% | 117.69% | |||
| Income Before Tax | 678.46% | 87.66% | |||
| Income Tax Expenses | 24.94% | 163.00% | |||
| Earnings from Continuing Operations | 330.74% | 69.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 330.74% | 69.83% | |||
| EBIT | 849.79% | 117.69% | |||
| EBITDA | -11.63% | 118.41% | |||
| EPS Basic | 331.52% | 69.87% | |||
| Normalized Basic EPS | -30.39% | 120.90% | |||
| EPS Diluted | 320.34% | 69.15% | |||
| Normalized Diluted EPS | -30.39% | 120.90% | |||
| Average Basic Shares Outstanding | -0.32% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.20% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||